Shanghai Denovo officially launches Phase I clinical study of a new TLR8 agonist DN1508052-01

2020-09-17

On September 10, Shanghai Denovo PharmaceuticalTechnology Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, held aTLR8 agonist DN1508052-01 Phase I clinical trial kick-off meeting at ShanghaiDongfang Hospital, officially launching the project's Phase I clinical study.



XW202009173.png



XW202009172.png


share